Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Galapagos Soothed By Gilead's $725m Up Front For AbbVie Reject Filgotinib

This article was originally published in Scrip

Executive Summary

Galapagos NV, which suffered a major shock in September when AbbVie decided not to exercise its option on their JAK1 inhibitor filgotinib, has secured $725m up front from Gilead Sciences Inc. for the promising rheumatoid arthritis treatment.

You may also be interested in...



Gilead Hopes Selectivity Will Ease Safety Labeling For Filgotinib

On pace to file selective JAK1 inhibitor filgotinib for US approval in RA by year’s end, Gilead says the drug’s safety profile may allow for a labeling advantage compared with other drugs in the class.

AbbVie To Take Flight From Galapagos As PELICAN Flounders?

Lacklustre top-line data from the PELICAN study raise concerns over AbbVie's commitment to Galapagos's cystic fibrosis franchise, and leaves rival Vertex even more securely in possession of the field.

Gilead Coming To The End Of HCV Road With Triple-Drug Regimen

Gilead reported an expected and continued sales decline in HCV – an area in which the company soon will be done with R&D, since unmet needs have been filled or will be soon by drug regimens from Gilead and its competitors. The company is hunting new assets, but taking a disciplined approach on price and quality.

Related Content

Topics

UsernamePublicRestriction

Register

ID1130765

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel